Its not only causing me stress, but it is making me angry. Starting Tuesday, CVS Caremark a major pharmacy benefit manager that serves as a middleman for health insurers, large employers and other payers to manage their prescription drug plans will stop covering Eli Lillys Zepbound, a blockbuster GLP-1 drug that has been approved by the US Food and Drug Administration since November 2023 for chronic weight management in adults with obesity or who are overweight
10.1002/jcb.27635 133
A diagnostic biomarker profile for fibromyalgia syndrome based on an NMR metabolomics study of selected patients and controls
Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients
Staresinic, M., Sebecic, B., Patrlj, L., Jadrijevic, S., Suknaic, S., Perovic, D., Aralica, G., Zarkovic, N., Borovic, S., Srdjak, M., Hajdarevic, K., Kopljar, M., Batelja, L., Boban-Blagaic, A., Turcic, I., Anic, T., Seiwerth, S., & Sikiric, P